Novel Drug Combinations in Lung Cancer: New Potential Synergies Between 5-FU and Repurposed Drugs
Source abstract
Abstract
The therapeutic potential of combining 5-FU with repurposed drugs such as Sildenafil, Tezosentan, Levosimendan, and Resveratrol was investigated in lung cancer treatment using the A549 cell line. This study aimed to enhance 5-FU efficacy while mitigating side effects and overcoming drug resistance. The cytotoxic effects of 5-FU were assessed via MTT assay, with an IC50 value of 5.03 µM for A549 cells. Subsequent experiments evaluated the impact of combining 5-FU with the aforementioned drugs on cell viability, clonogenic potential, and morphology. The results demonstrated that while Sildenafil and Tezosentan modestly improved 5-FU efficacy, Levosimendan reduced cell viability by 40% (p < 0.01) and Resveratrol by over 50% (p < 0.001), with clonogenicity reduced by up to 60% (p < 0.001). These findings suggest that combining 5-FU with Levosimendan or Resveratrol offers promising approaches for lung cancer therapy, potentially reducing the need for higher doses of 5-FU and minimizing associated toxicity. Future studies are warranted to elucidate the mechanisms underlying these interactions and assess their clinical relevance.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Lung Cancer Treatments and Mutations · Lung Cancer Research Studies · Lung Cancer Diagnosis and Treatment
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
OncoPharma Research Group, Center of Health Technology and Services Research (CINTESIS), Rua Doutor Plácido da Costa, 4200-450 Porto, Portugal
CINTESIS@RISE, Faculty of Medicine, University of Porto, Alameda Professor Hernâni Monteiro, 4200-319 Porto, Portugal
Intitute os Biomedical Sciences Abel Salazar (ICBAS), University of Porto, Rua de Jorge Viterbo Ferreira 228, 4050-313 Porto, Portugal
Department of Community Medicine, Health Information and Decision (MEDCIDS), Faculty of Medicine, University of Porto, Rua Doutor Plácido da Costa, 4200-450 Porto, Portugal
Funding
Fundo Europeu de Desenvolvimento Regional (FEDER) · Fundação para a Ciência e a Tecnologia (FCT) · the Faculty of Medicine, University of Porto (FMUP)
References (66)
Show source-provided references
1. Frequencies of EGFR single nucleotide polymorphisms in non-small cell lung cancer patients and healthy individuals in the Republic of Serbia: A preliminary study10.1007/s13277-016-4930-4 ↗
2. Biological and clinical significance of KRAS mutations in lung cancer: An oncogenic driver that contrasts with EGFR mutation10.1007/s10555-010-9209-4 ↗
3. Ethnicity affects EGFR and KRAS gene alterations of lung adenocarcinoma10.3892/ol.2015.3414 ↗
4. ALK-rearrangement in non-small-cell lung cancer (NSCLC)10.1111/1759-7714.12613 ↗
5. Diagnosis and Treatment of Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer10.1016/j.hoc.2016.08.012 ↗
6. ROS-1 Fusions in Non-Small-Cell Lung Cancer: Evidence to Date10.3390/curroncol29020057 ↗
7. Importance of ROS1 gene fusions in non-small cell lung cancer10.20517/cdr.2022.105 ↗
8. Targeting BRAF mutations in non-small cell lung cancer10.21037/tlcr.2019.10.22 ↗
9. Yan, N., Guo, S., Zhang, H., Zhang, Z., Shen, S., and Li, X. (2022). BRAF-Mutated Non-Small Cell Lung Cancer: Current Treatment Status and Future Perspective. Front. Oncol., 12.10.3389/fonc.2022.863043 ↗
10. Mogi, A., and Kuwano, H. (2011). TP53 mutations in nonsmall cell lung cancer. J. Biomed. Biotechnol., 2011.10.1155/2011/583929 ↗
11. Lung cancer: Diagnosis and management
12. Lung cancer: Epidemiology, etiology, and prevention10.1016/j.ccm.2011.09.001 ↗
13. Treatment of stage I and II non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines10.1378/chest.12-2359 ↗
14. Radiotherapy treatment for lung cancer: Current status and future directions10.1111/resp.13870 ↗
15. Role of chemotherapy and targeted therapy in early-stage non-small cell lung cancer10.1080/14737140.2018.1409624 ↗
16. Garg, P., Singhal, S., Kulkarni, P., Horne, D., Malhotra, J., Salgia, R., and Singhal, S.S. (2024). Advances in Non-Small Cell Lung Cancer: Current Insights and Future Directions. J. Clin. Med., 13.10.3390/jcm13144189 ↗
17. First-Line Immunotherapy for Non-Small-Cell Lung Cancer10.1200/JCO.21.01497 ↗
18. Hormone therapy and lung cancer mortality in women: Systematic review and meta-analysis10.1016/j.steroids.2016.12.005 ↗
19. The growing role of precision and personalized medicine for cancer treatment
20. Ghafouri-Fard, S., Abak, A., Tondro Anamag, F., Shoorei, H., Fattahi, F., Javadinia, S.A., Basiri, A., and Taheri, M. (2021). 5-Fluorouracil: A Narrative Review on the Role of Regulatory Mechanisms in Driving Resistance to This Chemotherapeutic Agent. Front. Oncol., 11.10.3389/fonc.2021.658636 ↗
21. Effectiveness of Adjuvant Chemotherapy with 5-FU/Leucovorin and Prognosis in Stage II Colon Cancer10.3393/jksc.2011.27.6.322 ↗
22. Palliative 5-fluorouracil-based chemotherapy for advanced colorectal cancer in the elderly: Results of a 10-year experience10.1097/00000421-200204000-00005 ↗
23. Sethy, C., and Kundu, C.N. (2021). 5-Fluorouracil (5-FU) resistance and the new strategy to enhance the sensitivity against cancer: Implication of DNA repair inhibition. Biomed. Pharmacother., 137.10.1016/j.biopha.2021.111285 ↗
24. Azwar, S., Seow, H.F., Abdullah, M., Faisal Jabar, M., and Mohtarrudin, N. (2021). Recent Updates on Mechanisms of Resistance to 5-Fluorouracil and Reversal Strategies in Colon Cancer Treatment. Biology, 10.10.3390/biology10090854 ↗
25. Cell cycle perturbation and acquired 5-fluorouracil chemoresistance
26. Predicting 5-fluorouracil toxicity in colorectal cancer patients from peripheral blood cell telomere length: A multivariate analysis10.1038/bjc.2012.421 ↗
27. Chang, C.-W., Liu, C.-Y., Lee, H.-C., Huang, Y.-H., Li, L.-H., Chiau, J.-S.C., Wang, T.-E., Chu, C.-H., Shih, S.-C., and Tsai, T.-H. (2018). Lactobacillus casei variety rhamnosus probiotic preventively attenuates 5-fluorouracil/oxaliplatin-induced intestinal injury in a syngeneic colorectal cancer model. Front. Microbiol., 9.10.3389/fmicb.2018.00983 ↗
28. Gastrointestinal adverse effects in advanced colorectal carcinoma patients treated with different schedules of FOLFOX10.7314/APJCP.2014.15.19.8089 ↗
29. Pharmacogenomics of fluorouracil-based chemotherapy toxicity10.1517/17425255.2015.1027684 ↗
30. 5-fluorouracil and cardiotoxicity: A review10.1177/1758835918780140 ↗
31. Combinational strategy for high-performance cancer chemotherapy10.1016/j.biomaterials.2018.04.027 ↗
32. Gilad, Y., Gellerman, G., Lonard, D.M., and O’Malley, B.W. (2021). Drug Combination in Cancer Treatment—From Cocktails to Conjugated Combinations. Cancers, 13.10.3390/cancers13040669 ↗
33. Multi-target therapeutics: When the whole is greater than the sum of the parts10.1016/j.drudis.2006.11.008 ↗
34. Quantitative methods for assessing drug synergism10.1177/1947601912440575 ↗
35. Irinotecan or oxaliplatin combined with leucovorin and 5-fluorouracil as first-line treatment in advanced colorectal cancer: A multicenter, randomized, phase II study10.1093/annonc/mdi193 ↗
36. A systematic review of the therapeutic effects of resveratrol in combination with 5-fluorouracil during colorectal cancer treatment: With a special focus on the oxidant, apoptotic, and anti-inflammatory activities10.1186/s12935-022-02561-7 ↗
37. Phosphodiesterase-5 (PDE5) Inhibitors In the Management of Erectile Dysfunction
38. Controlled delivery of sildenafil by β-Cyclodextrin-decorated sulfur-doped carbon nanodots: A synergistic activation of ROS signaling in tumors overexpressing PDE-510.1016/j.ijpharm.2023.123409 ↗
39. Repurposing of the Drug Tezosentan for Cancer Therapy10.3390/cimb45060325 ↗
40. Ribeiro, E., and Vale, N. (2023). Understanding the Clinical Use of Levosimendan and Perspectives on its Future in Oncology. Biomolecules, 13.10.3390/biom13091296 ↗
41. Ribeiro, E., Costa, B., Marques, L., Vasques-Nóvoa, F., and Vale, N. (2024). Enhancing Urological Cancer Treatment: Leveraging Vasodilator Synergistic Potential with 5-FU for Improved Therapeutic Outcomes. J. Clin. Med., 13.10.3390/jcm13144113 ↗
42. Resveratrol inhibits cancer cell proliferation by impairing oxidative phosphorylation and inducing oxidative stress10.1016/j.taap.2019.03.008 ↗
43. Brockmueller, A., Buhrmann, C., Shayan, P., and Shakibaei, M. (2023). Resveratrol induces apoptosis by modulating the reciprocal crosstalk between p53 and Sirt-1 in the CRC tumor microenvironment. Front. Immunol., 14.10.3389/fimmu.2023.1225530 ↗
44. Resveratrol inhibits NF-kB signaling through suppression of p65 and IkappaB kinase activities
45. Resveratrol downregulates PI3K/Akt/mTOR signaling pathways in human U251 glioma cells
46. Novel Strategies for Cancer Combat: Drug Combination Using Repurposed Drugs Induces Synergistic Growth Inhibition of MCF-7 Breast and HT-29 Colon Cancer Cells10.3390/cimb44100335 ↗
47. Combining repurposed drugs to treat colorectal cancer10.1016/j.drudis.2021.09.012 ↗
48. Duarte, D., Nunes, M., Ricardo, S., and Vale, N. (2022). Combination of Antimalarial and CNS Drugs with Antineoplastic Agents in MCF-7 Breast and HT-29 Colon Cancer Cells: Biosafety Evaluation and Mechanism of Action. Biomolecules, 12.10.3390/biom12101490 ↗
49. Pan, X., Zhang, X., Sun, H., Zhang, J., Yan, M., and Zhang, H. (2013). Autophagy inhibition promotes 5-fluorouraci-induced apoptosis by stimulating ROS formation in human non-small cell lung cancer A549 cells. PLoS ONE, 8.10.1371/journal.pone.0056679 ↗
50. Epigenetic Mechanism of Enrichment of A549 Lung Cancer Stem Cells with 5-Fu10.2147/OTT.S233129 ↗
51. In vitro and in vivo evaluation of macromolecular prodrug GC-FUA based nanoparticle for hepatocellular carcinoma chemotherapy10.1080/10717544.2016.1264499 ↗
52. Development of a 5-FU modified miR-129 mimic as a therapeutic for non-small cell lung cancer10.1016/j.omto.2023.02.007 ↗
53. β-Adrenergic Signaling in Lung Cancer: A Potential Role for Beta-Blockers10.1007/s11481-019-09891-w ↗
54. Resveratrol inhibits the growth of tumor cells under chronic stress via the ADRB-2-HIF-1α axis
55. Resveratrol mediates cell cycle arrest and cell death in human esophageal squamous cell carcinoma by directly targeting the EGFR signaling pathway10.3892/ol.2016.5391 ↗
56. Epidermal growth factor receptor expression affects proliferation and apoptosis in non-small cell lung cancer cells via the extracellular signal-regulated kinase/microRNA 200a signaling pathway
57. Sustained proliferation in cancer: Mechanisms and novel therapeutic targets10.1016/j.semcancer.2015.02.006 ↗
58. Cell Proliferation and Cytotoxicity Assays10.2174/1389201017666160808160513 ↗
59. Resveratrol at anti-angiogenesis/anticancer concentrations suppresses protein kinase G signaling and decreases IAPs expression in HUVECs
60. An In Vitro Investigation of the Antiproliferative and Antimetastatic Effects of Levosimendan: Potential Drug Repurposing for Cervical Cancer10.3390/cimb46070391 ↗
61. Inhibition of NF-κB signaling unveils novel strategies to overcome drug resistance in cancers10.1016/j.drup.2023.101042 ↗
62. PI3K/AKT pathway as a key link modulates the multidrug resistance of cancers10.1038/s41419-020-02998-6 ↗
63. 4′-Chloro-3,5-dihydroxystilbene, a resveratrol derivative, induces lung cancer cell death10.1038/aps.2009.182 ↗
64. Resveratrol induces cell cycle arrest via a p53-independent pathway in A549 cells10.3892/mmr.2014.3100 ↗
65. Resveratrol inhibits proliferation, migration and invasion via Akt and ERK1/2 signaling pathways in renal cell carcinoma cells10.1016/j.biopha.2017.12.029 ↗
66. Roy, S.K., Chen, Q., Fu, J., Shankar, S., and Srivastava, R.K. (2011). Resveratrol inhibits growth of orthotopic pancreatic tumors through activation of FOXO transcription factors. PLoS ONE, 6.10.1371/journal.pone.0025166 ↗